Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma

Inclusion Criteria: * Patients with non-Hodgkin's B-cell lymphoma (NHL) including follicular, large cell and Mantle cell lymphoma will be included. * Patients in complete clinical remission and determined to have no evidence of active disease (NED). * Ambulatory, medically stable persons; community dwelling; able to give informed consent and available for all study visits; able to understand and comply with planned study procedures; ECOG performance status less than or equal to 2. * Medically stable subjects may have underlying illnesses such as hypertension, diabetes, ischemic heart disease, or hypothyroidism, but their symptoms/signs are controlled with medical therapy. * Patients with a non-metastatic secondary solid tumor or malignancies not currently (\< 3 months) being treated will be included. * Patients greater than or equal to 18 years of age who have given informed consent and signed the IRB approved informed consent. Exclusion Criteria: * Patients with Hodgkin's disease, and T-cell lymphoma. * Patients undergoing antineoplastic therapy. * Patients who have received chemotherapy within the past 3 months. * Individuals who were given rituximab (ibritumomab tiuxetan) in \< 6 months. * Patients receiving systemic corticosteroids and/or high-dose inhaled steroids (\>800 mcg per day of beclomethasone dipropionate or equivalent). * Splenectomized individuals will not be included. * Known allergy to eggs or other components of vaccine (e.g., thimerosal). * Acute or chronic condition that (in the opinion of the investigator) would render vaccination unsafe or would interfere with the evaluation of responses (including but not limited to the following: acute febrile illness, known chronic liver disease; significant renal disease; oxygen-dependent chronic lung disease, New York Heart Association Functional Class III or IV dyspnea; unstable or progressive neurologic disorder; insulin-dependent diabetes mellitus). * Concomitant use of investigational vaccines and/or other medications within 4 weeks prior to study entry, or expected use of experimental or licensed vaccines or blood/blood products prior to study completion. * Previous exposure to parenteral immunoglobulins or other blood product within 6 months prior to enrollment into the study. * Subject is enrolled in a conflicting clinical trial. * Use of experimental vaccines or medications within one month of study entry. * Any acute or chronic condition which in the opinion of the investigator would render vaccination unsafe or interfere with the evaluation of response. * Patients with a known history or risk factors (IV drug abuse or casual sex within the past year) of Hepatitis B, Hepatitis C, or Human Immunodeficeincy Virus.